Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gerald M Reaven, Stanford University
ClinicalTrials.gov Identifier:
NCT01784965
First received: February 4, 2013
Last updated: NA
Last verified: February 2013
History: No changes posted